Marathon of Hope Cancer Centres Network publishes ‘marker paper’ in esteemed journal Cancer Cell
With its first landmark publication in a high-profile scientific journal, The Marathon of Hope Cancer Centres Network (MOHCCN) is aiming to generate more collaboration both within Canada and around the world. The paper details the creation of the Network, its vision, and how it has united patients, researchers, clinicians, donors, and administrators nationwide to formulate a cohesive, pan-Canadian strategy for advancing precision oncology.
OICR is a MOHCCN partner and numerous OICR researchers and projects are involved in the Network. Many of the Institute’s contributions to MOHCCN flow through the Princess Margaret Cancer Consortium (PM2C), a partnership between OICR, the Princess Margaret Cancer Centre – University Health Network, Queen’s University and the Canadian Cancer Trials Group.
PM2C brings together clinicians, pathologists, data and translational scientists, bioinformaticians, and software developers from across Ontario to build retrospective and prospective patient cohorts and guide data interpretation in the appropriate clinical and molecular context.
“The MOHCCN project greatly advances Canada’s leadership in precision oncology by accelerating the development of diagnostic tests that will allow cancer doctors and patients to choose the therapy that has the greatest chance for success while minimizing the risk of unwanted side effects,” says Dr. Lincoln Stein, Acting Scientific Director and Head, Adaptive Oncology at OICR, and contributor to MOHCCN. “I am proud that OICR plays a key role in the MOHCCN project by providing more than a third of the project’s genome sequencing capacity and providing guidance to the project via its participation in the steering committee and leadership on multiple policy-setting working groups.”
